Revenue: As of FY2025, the actual value is USD 0.EPS: As of FY2025, the actual value is USD -1.26.EBIT: As of FY2025, the actual value is USD -5.106 M.Lixte Biotechnology Holdings, Inc. has not yet commenced any revenue-generating operations and relies on equity capital to fund its operating requirements. The company reported a net loss of - $6,009,520 for the year ended December 31, 2025, compared to - $3,585,965 for the year ended December 31, 2024. The accumulated deficit as of December 31, 2025, was - $58,077,213, up from - $52,067,693 at December 31, 2024.<h4>LB-100 (Pharmaceuticals) Operational Metrics</h4><ul><li>Research and Development Costs: Total research and development costs were - $254,919 in 2025, a 64.9% decrease from - $726,232 in 2024, primarily due to a - $133,655 reduction in preclinical research.<ul><li>Clinical and related oversight costs were - $57,193 in 2025 and - $377,958 in 2024.</li><li>Regulatory service costs were - $9,050 in 2025 and - $18,836 in 2024.</li><li>Preclinical research costs were - $188,675 in 2025 and - $329,438 in 2024.</li></ul></li><li>Patent and License Agreements: The company paid the NIH a non-creditable, non-refundable license issue royalty of - $50,000, and the first minimum annual royalty was - $25,643. Subsequent annual royalties of - $30,000 are due each January 1. Costs incurred for these obligations were - $30,000 in 2025 and - $75,643 in 2024. The aggregate commitment for these agreements is approximately - $1,765,000 as of December 31, 2025, expected over about nineteen years.</li><li>Clinical Trial Commitments: As of December 31, 2025, remaining financial contractual commitments for clinical trial agreements and monitoring aggregated - $496,000, expected through December 31, 2027.<ul><li>GEIS Clinical Trial: The company’s financial obligation of approximately - $3,095,000 for the randomized Phase 2 portion was relieved effective March 11, 2025. The remaining commitment for the Phase 1b portion was approximately - $293,000 as of December 31, 2025, to be incurred in Q1 2026. Costs incurred were - $0 in 2025 and - $268,829 in 2024.</li><li>MD Anderson Clinical Trial Monitoring: Estimated costs are approximately - $95,000, with incurred costs of - $21,706 in 2025 and - $26,763 in 2024. The aggregate commitment was approximately - $48,000 as of December 31, 2025, expected through December 31, 2027.</li><li>Netherlands Cancer Institute Clinical Trial Monitoring: Estimated costs are approximately - $106,380, with incurred costs of - $0 in 2025 and - $20,191 in 2024. The aggregate commitment was approximately - $88,000 as of December 31, 2024, expected through May 31, 2027.</li></ul></li></ul><h4>Liora Technologies Europe Ltd. (Proton Cancer Therapy) Operational Metrics</h4><ul><li>Revenue: Liora currently has no revenues.</li><li>Acquisition Costs: The acquisition in November 2025 included a cash portion of - $440,000 and digital assets worth - $2,637,360 transferred to the seller. Capitalized transaction costs totaled - $95,102.</li><li>Recommissioning Costs: The company expects to incur approximately - $2 million over the next twenty-four months to recommission and update the LiGHT system.</li><li>Lease Obligations: Annual lease obligations are approximately - $787,278 (£590,384.79) under an operating lease for the Daresbury Laboratory facility.</li></ul><h4>Company-Wide Financial Metrics</h4><ul><li>General and Administrative Costs: These costs increased by 70.0% to - $4,852,702 in 2025 from - $2,846,557 in 2024, primarily due to a - $1,054,443 increase in the fair value of vested stock options and a - $696,097 increase in other consulting and professional fees.</li><li>Interest Income: - $7,388 in 2025, compared to - $7,048 in 2024.</li><li>Interest Expense: - $9,158 in 2025, compared to - $16,821 in 2024.</li><li>Realized Loss on Digital Assets: A loss of - $904,394 was realized in 2025 due to the disposal of Bitcoin and Ethereum as part of the Liora acquisition.</li><li>Foreign Currency Gain (Loss): A gain of - $525 was reported in 2025, compared to a loss of - $3,403 in 2024.</li><li>Cash Flow from Operating Activities: The company used - $3,070,618 in 2025, compared to - $3,164,536 in 2024.</li><li>Cash Flow from Investing Activities: The company used - $3,172,462 in 2025, related to the Liora acquisition and digital asset purchases, compared to - $0 in 2024.</li><li>Cash Flow from Financing Activities: The company provided - $10,311,000 in 2025 from securities offerings, compared to - $0 in 2024.</li><li>Cash Balance: The cash balance was - $5,106,872 as of December 31, 2025.</li><li>Working Capital: Working capital was - $3,845,268 at December 31, 2025, an increase of - $3,018,049 from - $827,219 at December 31, 2024.</li></ul><h4>Outlook / Guidance</h4>Lixte Biotechnology Holdings, Inc. requires significant additional financing to fund operations and complete product development, with existing cash resources expected to last through approximately September 30, 2026. The company anticipates needing to raise additional capital by mid-2026 to fund its business plan through 2027 and does not expect to generate sustainable operating revenues for several years, if ever. Management is actively pursuing additional financing alternatives, including equity/debt financings and potential strategic transactions, but there is no assurance of availability on acceptable terms.

Lixte Biotechnology | 10-K: FY2025 Revenue: USD 0